Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

OTCMKTS: SDZNY

    • Home
    • OTCMKTS: SDZNY
Company

Sandoz Expands Antibiotics Production with New Austrian Factory

Fineline Cube Mar 25, 2024

Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics...

Company Drug Legal / IP

BeiGene Launches Legal Action Against Sandoz and MSN Over Brukinsa Patent Infringement

Fineline Cube Mar 11, 2024

BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has initiated patent...

Recent updates

  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
  • Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication
  • Harbour BioMed Receives FDA Clearance for Phase I Trial of Novel B7H4xCD3 Bispecific Antibody HBM7004
  • Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Others

Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication

Company Drug

Harbour BioMed Receives FDA Clearance for Phase I Trial of Novel B7H4xCD3 Bispecific Antibody HBM7004

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.